In the last few years, the discoveries in pharmaceutical nanotechnology have triggered a revolution in the field of therapeutic, delivering an abundance of novel applications and actual approaches of metallic nanoformulations for the treatment and diagnosis of tenacious diseases. From this point of view, gold nanoparticles (GN) have been awarded an attractive platform for the development of efficient multifunctional therapeutic, controlled release systems, targeted delivery and diagnostic. The objective of this research was to prepare etoposide-loaded gold nanoparticles (E-GN) by incorporating of etoposide in to the functionalized GN by using different biocompatible polymers. In the present study, GN suspension was prepared by inverse citrate reduction method. Polymeric suspensions 19 (PGN 1-19) were prepared and characterized by atomic force microscopy measurement (AFM). The obtained results indicated that PGN10, PGN13, PGN17 and PGN19 with the preferable polymers and their concentration of (1-mg/mL HPMC-E5, 1-mg/mL PVA, 1.5 mg/mL gelatin and 0.5: 0.5 mg/mL of HPMC-E5: PVA combination) respectively, showed the better morphology, particles size (PS), and particles size distribution (PSD). Subsequently, eight formulas were prepared and optimized through the study of various variables as PS, PSD, etoposide loading efficiency (LE) and in-vitro dissolution profile. F7 revealed a greater LE of 99.39% with higher loading capacity (1 mg/mL) and in-vitro dissolution with controlled mode also, AFM results showed smooth surface nanoparticles, average PS (24.43 nm) with uniform PSD (9.84%). In addition, the result of transmission electron microscopy (TEM) revealed a spherical uniform shape with zeta potential of -34.13. In conclusion, polymeric functionalization of GN improved the etoposide loading efficiency and capacity and controlled the in-vitro dissolution profile and enhanced their colloidal stability.